Do the dissociative side effects of ketamine mediate its antidepressant effects?

被引:204
作者
Luckenbaugh, David A. [1 ]
Niciu, Mark J. [1 ]
Ionescu, Dawn F. [1 ]
Nolan, Neal M. [1 ]
Richards, Erica M. [1 ]
Brutsche, Nancy E. [1 ]
Guevara, Sara [1 ]
Zarate, Carlos A. [1 ]
机构
[1] NIMH, Expt Therapeut & Pathophysiol Branch, Intramural Res Program, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Blood pressure; Psychotomimetic; Predictors; Major depressive disorder; Bipolar depression; Ketamine; STRIATAL DOPAMINE RELEASE; D-ASPARTATE ANTAGONIST; POSITRON-EMISSION-TOMOGRAPHY; NMDA ANTAGONIST; RANDOMIZED-TRIAL; RATING-SCALE; SYMPTOMS; ACTIVATION; DEPRESSION; EFFICACY;
D O I
10.1016/j.jad.2014.02.017
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The N-methyl-D-aspartate receptor antagonist ketamine has rapid antidepressant effects in major depression. Psychotomimetic symptoms, dissociation and hemodynamic changes are known side effects of ketamine, but it is unclear if these side effects relate to its antidepressant efficacy. Methods: Data from 108 treatment-resistant inpatients meeting criteria for major depressive disorder and bipolar disorder who received a single subanesthetic ketamine infusion were analyzed. Pearson correlations were performed to examine potential associations between rapid changes in dissociation and psychotomimesis with the Clinician-Administered Dissociative States Scale (CADSS) and Brief Psychiatric Rating Scale (BPRS), respectively, manic symptoms with Young Mania Rating Scale (YMRS), and vital sign changes, with percent change in the 17-item Hamilton Depression Rating scale (HDRS) at 40 and 230 min and Days 1 and 7. Results: Pearson correlations showed significant association between increased CADSS score at 40 min and percent improvement with ketamine in HDRS at 230 min (r=-0.35, p=0.007) and Day 7 (r=-0.41, p=0.01). Changes in YMRS or BPRS Positive Symptom score at 40 min were not significantly correlated with percent HDRS improvement at any time point with ketamine. Changes in systolic blood pressure, diastolic blood pressure, and pulse were also not significantly related to HDRS change. Limitations: Secondary data analysis, combined diagnostic groups, potential unblinding. Conclusions: Among the examined mediators of ketaminers antidepressant response, only dissociative side effects predicted a more robust and sustained antidepressant. Prospective, mechanistic investigations are critically needed to understand why intra-infusion dissociation correlates with a more robust antidepressant efficacy of ketamine. Published by Elsevier B.V.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 36 条
  • [21] SUBANESTHETIC EFFECTS OF THE NONCOMPETITIVE NMDA ANTAGONIST, KETAMINE, IN HUMANS - PSYCHOTOMIMETIC, PERCEPTUAL, COGNITIVE, AND NEUROENDOCRINE RESPONSES
    KRYSTAL, JH
    KARPER, LP
    SEIBYL, JP
    FREEMAN, GK
    DELANEY, R
    BREMNER, JD
    HENINGER, GR
    BOWERS, MB
    CHARNEY, DS
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 1994, 51 (03) : 199 - 214
  • [22] Cellular mechanisms underlying the antidepressant effects of ketamine:: Role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
    Maeng, Sungho
    Zarate, Carlos A., Jr.
    Du, Jing
    Schloesser, Robert J.
    McCammon, Joseph
    Chen, Guang
    Manji, Husseini K.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 63 (04) : 349 - 352
  • [23] Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
    Mathew, Sanjay J.
    Murrough, James W.
    aan het Rot, Marije
    Collins, Katherine A.
    Reich, David L.
    Charney, Dennis S.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (01) : 71 - 82
  • [24] Messer M, 2010, J NEUROPSYCH CLIN N, V22, P442, DOI 10.1176/appi.neuropsych.22.4.442
  • [25] Moghaddam B, 1997, J NEUROSCI, V17, P2921
  • [26] Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial
    Murrough, James W.
    Losifescu, Dan V.
    Chang, Lee C.
    Al Jurdi, Rayan K.
    Green, Charles E.
    Perez, Andrew M.
    Lqbal, Syed
    Pillemer, Sarah
    Foulkes, Alexandra
    Shah, Asim
    Charney, Dennis S.
    Mathew, Sanjay J.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2013, 170 (10) : 1134 - 1142
  • [27] OVERALL JE, 1962, PSYCHOL REP, V10, P799
  • [28] An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
    Preskorn, Sheldon H.
    Baker, Bryan
    Kolluri, Sheela
    Menniti, Frank S.
    Krams, Michael
    Landen, Jaren W.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (06) : 631 - 637
  • [29] Smith GS, 1998, NEUROPSYCHOPHARMACOL, V18, P18
  • [30] Sos P, 2013, NEUROENDOCRINOL LETT, V34, P287